Author

D. Abou

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:mouse· 5 Research Focus:drug response / drug discovery· 4 Research Focus:host-pathogen & immune response· 3 Assay:imaging· 3 Research Focus:cell type annotation· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1

Frequent Co-Authors

D. L. Thorek· 5 shared D. Ulmert· 4 shared B. W. Simons· 2 shared C. M. Storey· 2 shared J. E. Park· 2 shared K. Herrmann· 2 shared M. Altai· 2 shared N. F. Turtle· 2 shared

Activity by Year

2018-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

D. L. Thorek

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Development of a LRRC15-Targeted Radio-Immunotheranostic Approach to Deplete Pro-tumorigenic Mechanisms and Immunotherapy Resistance

C. M. Storey, M. Altai, K. M. Lueckerath, W. Zedan, H. Zhu, M. Trajkovic-Arsic, J. E. Park, N. Peekhaus, J. Siveke, H. Lilljebjorn, D. Abou, H. L. Marks, E. Ulmert, H. Lilja, A. Ridley, , D. Ulmert

This paper develops a radio-theranostic approach targeting LRRC15 to image and treat cancer, showing tumor reduction and reversal of immunotherapy resistance.

bioRxiv · Jan 30, 2024 · PreprintPharmacology & Toxicology

Assessing Functional Androgen Receptor Pathway Activity in Response to Radiotherapy Using hK2-targeted PET Imaging

C. M. Storey, M. Altai, M. Bicak, D. R. Veach, K. Lueckerath, G. Adrian, M. R. McDevitt, T. Kalidindi, J. E. Park, K. Herrmann, D. Abou, W. Zedan, N. Peekhaus, R. J. Klein, R. Damoiseaux, , D. Ulmert

This study evaluates if [89Zr]11B6-PET can detect EBRT-induced AR pathway activation in PCa using hK2 as a biomarker.

bioRxiv · Jun 23, 2022 · PreprintCancer Biology

-Labeled PARP-1 PET Imaging of PSMA Targeted Alpha Particle Radiotherapy Response

H. Zhang, D. Abou, A. Villmer, N. Benabdallah, W. Jiang, D. Ulmert, S. Carlin, B. E. Rogers, N. F. Turtle, M. McDevitt, B. Baumann, B. W. Simons, D. Zhou, D. L. Thorek

This study uses [18F]-PARPZ PET imaging to assess alpha particle radiotherapy response in prostate cancer xenografts by tracking PARP-1 expression changes.

bioRxiv · Mar 16, 2022Cancer Biology

JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy

M. T. Nedelcovych, R. P. Dash, Y. Wu, E. Y. Choi, R. S. Lapidus, P. Majer, D. Abou, M.-F. Penet, A. Nikolopoulou, A. Amor-Coarasa, J. Babich, D. L. Thorek, R. Rais, C. Kratochwil, B. S. Slusher

This paper describes the development of JHU-2545, a prodrug that selectively shields salivary glands and kidneys from PSMA-targeted radiotherapy, improving safety without affecting tumor uptake.

bioRxiv · Feb 15, 2019 · PreprintPharmacology & Toxicology

PSMA Expression in the Hi-Myc Model; Extended Utility of a Representative Model of Prostate Adenocarcinoma for Biological Insight and as a Drug Discovery Tool

B. W. Simons, N. F. Turtle, D. Ulmert, D. Abou, D. L. Thorek

The paper shows that mPSMA is highly expressed in the Hi-Myc mouse model of prostate cancer, from early lesions to adenocarcinoma, supporting its use as a model for biological study and drug discovery.

bioRxiv · Oct 16, 2018Cancer Biology